Imaging AI in Arizona

Caris Life Sciences is a precision medicine and AI-driven TechBio company founded in 2008, headquartered in Phoenix, Arizona. The company specializes in molecular profiling and oncology diagnostics, operating a CLIA-certified laboratory that has processed over 1 million cases and 6.5 million tests. Caris develops comprehensive genomic and transcriptomic assays combining whole exome sequencing (WES), whole transcriptome sequencing (WTS), and protein analysis across 23,000+ genes. The company offers two primary clinical offerings: Caris Assure, a blood-based liquid biopsy utilizing circulating nucleic acid sequencing (cNAS) for pan-cancer profiling, and Caris MI Profile, a tissue-based assay delivering DNA, RNA, and protein analysis with AI-predictive algorithms. Caris maintains one of the largest multimodal databases globally—over 740,000 matched molecular and clinical outcomes records—which powers its proprietary Molecular AI platform. This AI engine generates 220+ interpretations and has measured over 50 billion molecular markers. The company serves oncologists, cancer patients, and biopharma partners across the care continuum: disease detection, therapy selection, and treatment monitoring. Caris publishes extensively (1,200+ peer-reviewed publications) and maintains partnerships with 45+ NCI-Designated Cancer Centers and 95+ members worldwide. The platform enables personalized, precision-oncology treatment decisions by revealing molecular blueprints and predicting individual patient response to therapies.

JelloX Biotech Inc. is a Taiwan-based biotech company specializing in 3D digital pathology imaging and AI-assisted diagnostic software. The company develops Metalite, a proprietary 3D pathology analysis software platform integrated with artificial intelligence modules designed to support precision medicine diagnostics. Metalite assists pathologists in evaluating clinical tissue specimen morphology variations and identifying tumor-targeted molecular distribution patterns, thereby enhancing cancer diagnosis accuracy and supporting new drug development workflows. The company positions itself as a pioneer in 3D intelligent pathology, leveraging innovative technology to enable precise medical diagnosis and treatment planning. JelloX markets its solutions internationally, collaborating with renowned hospitals and healthcare institutions to expand its global presence. The company emphasizes rigorous scientific validation and quality compliance as core values, with a commitment to building an integrated ecosystem of digital pathology and AI-enabled medical solutions. Services include 3D pathological image analysis and cancer cell detection support for clinical laboratories and research institutions.

DeepLook Medical develops FDA-cleared imaging enhancement software designed to improve diagnostic clarity and reduce unnecessary follow-up imaging in mammography. The company's flagship product, DL Precise™, integrates seamlessly into existing radiology workflows to visualize deep breast tissue that may be difficult for radiologists to detect with the human eye alone. The technology addresses a significant clinical gap: approximately 42 million mammograms are performed annually in the United States, yet 12 million require additional screening due to image ambiguity and operator-dependent analysis. DL Precise™ is embedded within leading medical imaging platforms including partnerships with major equipment manufacturers and imaging software providers. The solution targets three stakeholder groups: radiologists seeking improved diagnostic confidence and workflow efficiency, healthcare providers aiming to increase revenue through better diagnostic accuracy, payers looking to minimize reimbursement costs by reducing unnecessary imaging procedures, and patients benefiting from fewer unnecessary tests and greater diagnostic reassurance. The technology has been commercially validated through partnerships with established medical device and software companies. DeepLook Medical is based in Scottsdale, Arizona.